ASLAN Pharmaceuticals

You are now leaving our web site.

The Website may contain links to or from other websites, over which ASLAN has no control. These linked sites are for your convenience only and you access them at your own risk.

ASLAN is not responsible for the content of the linked sites. ASLAN does not in any way endorse the linked sites.

I understand

News & Publications

Read about our latest product developments and partnerships, industry advances and events.

News

ASLAN Pharmaceuticals Announces Late-breaker Presentation of Data From Eblasakimab Proof-of-Concept Study at the 2022 American Academy of Dermatology Annual Meeting

ASLAN Pharmaceuticals (NASDAQ: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced the oral presentation of data from the completed Phase 1b multiple-ascending-dose (MAD) study that established proof of concept for eblasakimab (ASLAN004) in moderate-to-severe atopic dermatitis (AD) during the late-breaking research session at the 2022 American Academy of Dermatology (AAD) Annual Meeting on March 26, 2022, in Boston, Massachusetts. The data were presented by Dr Andrew Blauvelt, President, Oregon Medical Research Center.

For more information, please refer to the press release.